Status:
COMPLETED
Risk Factors for the Recurrent Postoperative Macular Edema Treated With OZURDEX
Lead Sponsor:
Peking University
Conditions:
Macular Edema
Eligibility:
All Genders
Brief Summary
Patients who were diagnosed as postoperative CME and administrated with intravitreal OZURDEX injection were reviewed. Outcome will include best-corrected visual acuity (BCVA), intraocular pressure (IO...
Detailed Description
Patients who were diagnosed as postoperative CME after uneventful intraocular surgery and administrated with intravitreal OZURDEX injection were reviewed. All patients underwent ophthalmic examination...
Eligibility Criteria
Inclusion
- patients who were diagnosed as postoperative CME after successful phacoemulsification or vitrectomy and administrated with intravitreal dexamethasone implant (OZURDEX, Allergan, Inc, California, USA) injection were reviewed.
Exclusion
- patients with retinal vascular diseases, including retinal vein occlusion (RVO), diabetic retinopathy (DR), hypertensive retinopathy, retinal artery occlusion (RAO), Coats disease, Eales disease;
- patients with macular disease before surgery, such as age-related macular degeneration (ARMD), macular choroidal neovascularization (CNV), myopic macular degeneration, macular hole (MH), epiretinal membrane(ERM);
- patients with uveitis before surgery, including anterior, intermediate, posterior and generalized uveitis;
- patients with autoimmune disease, such as ankylosing spondylitis (AS), Vogt-Koyanagi-Harada (VKH) disease, Behcet disease.
Key Trial Info
Start Date :
July 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05372562
Start Date
July 1 2017
End Date
April 30 2022
Last Update
May 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Third Hosipital
Beijing, Beijing Municipality, China, 100191